Autobio Diagnostics Co Ltd Asset Resilience Ratio

Latest as of March 2026: 1.51%

Autobio Diagnostics Co Ltd asset resilience ratio. Autobio Diagnostics Co Ltd (603658) has an Asset Resilience Ratio of 1.51% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of Autobio Diagnostics Co Ltd to measure how many days the company can operate on defensive assets alone.

Liquid Assets

CN¥185.18 Million
≈ $27.10 Million USD Cash + Short-term Investments

Total Assets

CN¥12.24 Billion
≈ $1.79 Billion USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio of Autobio Diagnostics Co Ltd (2016–2025)

Asset resilience ratio of Autobio Diagnostics Co Ltd from 2016 to 2025. This chart shows how Autobio Diagnostics Co Ltd's Asset Resilience Ratio has changed over time. Read 603658 total debt and obligations for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Autobio Diagnostics Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of Autobio Diagnostics Co Ltd.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥185.18 Million 1.51%
Total Liquid Assets CN¥185.18 Million 1.51%

Asset Resilience Insights

  • Limited Liquidity: Autobio Diagnostics Co Ltd maintains only 1.51% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Autobio Diagnostics Co Ltd Industry Peers by Asset Resilience Ratio

Compare Autobio Diagnostics Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Demant A/S
CO:DEMANT
Medical Devices -2.59%
Shanghai Sanyou Medical Co Ltd
SHG:688085
Medical Devices 7.69%
CareRay Digital Medical Technology Co Ltd
SHG:688607
Medical Devices 16.21%
Cleo Diagnostics Ltd
AU:COV
Medical Devices 94.64%
Memphasys Ltd
AU:MEM
Medical Devices 0.00%
Cochlear Ltd
AU:COH
Medical Devices 9.76%
Anteris Technologies Global Corp
AU:AVR
Medical Devices 33.27%
Polynovo Ltd
AU:PNV
Medical Devices 0.04%

Autobio Diagnostics Co Ltd Asset Resilience Ratio by Year (2016–2025)

Autobio Diagnostics Co Ltd asset resilience ratio by year from 2016 to 2025. The table below shows the annual Asset Resilience Ratio data for Autobio Diagnostics Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 4.09% CN¥502.10 Million
≈ $73.47 Million
CN¥12.29 Billion
≈ $1.80 Billion
-26.01pp
2024-12-31 30.09% CN¥3.57 Billion
≈ $522.93 Million
CN¥11.88 Billion
≈ $1.74 Billion
+3.83pp
2023-12-31 26.26% CN¥3.03 Billion
≈ $443.98 Million
CN¥11.55 Billion
≈ $1.69 Billion
+26.18pp
2021-12-31 0.08% CN¥7.34 Million
≈ $1.07 Million
CN¥9.23 Billion
≈ $1.35 Billion
-0.98pp
2020-12-31 1.06% CN¥85.89 Million
≈ $12.57 Million
CN¥8.14 Billion
≈ $1.19 Billion
-1.77pp
2019-12-31 2.82% CN¥120.16 Million
≈ $17.58 Million
CN¥4.26 Billion
≈ $622.91 Million
+2.79pp
2018-12-31 0.04% CN¥931.48K
≈ $136.30K
CN¥2.66 Billion
≈ $388.74 Million
-17.71pp
2017-12-31 17.74% CN¥388.09 Million
≈ $56.79 Million
CN¥2.19 Billion
≈ $320.07 Million
-25.78pp
2016-12-31 43.53% CN¥792.80 Million
≈ $116.01 Million
CN¥1.82 Billion
≈ $266.53 Million
--
pp = percentage points

About Autobio Diagnostics Co Ltd

SHG:603658 China Medical Devices
Market Cap
$3.32 Billion
CN¥22.72 Billion CNY
Market Cap Rank
#4483 Global
#671 in China
Share Price
CN¥39.76
Change (1 day)
-0.58%
52-Week Range
CN¥28.72 - CN¥39.99
All Time High
CN¥131.73
About

Autobio Diagnostics Co., Ltd. engages in the research and development, production, marketing, sale, and service of clinical diagnostic products in China and internationally. The company offers immunoassay, biochemistry, and microbiology products; reagents and instruments; and technical and support, and training services, as well as engages in biology research and development activities. Its immun… Read more